This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy | MicrobiomeTrials
← Back to trials NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy ENROLLING_BY_INVITATION PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-04-20Est. Completion: 2031-12
Enrollment target: 18 participantsLocations Fondazione Serena ETS - Centro Clinico NeMO Milano, Milan, Italy, Italy UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy, Italy Leids Universitair Medisch Centrum, Leiden, Netherlands, Netherlands Hospital Viamed Santa Angela De la Cruz, Seville, Spain, Spain Yeditepe University Kosuyolu Hospital, Istanbul, Turkey, Turkey (Türkiye) Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, United Kingdom Other microbiome trials you might be interested in Duchenne Muscular Dystrophy
This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerabi…
Leuven, Belgium Est. completion Feb 2028
Duchenne Muscular Dystrophy
The primary objective of this study is to provide UC-MSC treatment to patients with DMD.
Secondary objectives will be t…
Dallas, United States Est. completion Oct 31, 2028